Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51.

    Article  CAS  PubMed  Google Scholar 

  2. Dyson MH, Thomson S, Inagaki M, Goto H, Arthur SJ, Nightingale K et al. MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J Cell Sci 2005; 118: 2247–2259.

    Article  CAS  PubMed  Google Scholar 

  3. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP . Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53–61.

    Article  CAS  PubMed  Google Scholar 

  4. Nishioka C, Ikezoe T, Takeshita A, Yang J, Tasaka T, Yang Y et al. ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244. Leukemia 2007; 21: 1308–1310.

    Article  CAS  PubMed  Google Scholar 

  5. Prigent C, Dimitrov S . Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003; 116: 3677–3685.

    Article  CAS  PubMed  Google Scholar 

  6. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S et al. Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781–2790.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grant-in-aid from the Ministry of Education, Culture Sports, Science, and Technology of Japan; Kanae Foundation for the Promotion of Medical Science; Public Trust of Haraguchi Memorial Cancer Research Fund and the Fund for Academic Research from Kochi University. HPK is supported by NIH grants, as well as the Inger Fund and the Parker Hughes Trust.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T Ikezoe.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nishioka, C., Ikezoe, T., Yang, J. et al. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22, 1449–1452 (2008). https://doi.org/10.1038/sj.leu.2405079

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405079

This article is cited by

Search

Quick links